Overview
- Peptide (C)RSYSTTYEERNITGTR, corresponding to amino acid residues 202 - 217 of human ASCT2 (Accession Q15758). 2nd extracellular loop.
- Human MCF-7 breast adenocarcinoma, Colo-205 colorectal adenocarcinoma, PANC-1 pancreas ductal adenocarcinoma, and Malme-3M melanoma cell lysates (1:200-1:1000).
- Western blot analysis of human MCF-7 breast adenocarcinoma (lanes 1 and 5), human Colo-205 colorectal adenocarcinoma (lanes 2 and 6), human PANC-1 pancreas ductal adenocarcinoma (lanes 3 and 7) and human Malme-3M melanoma cell line lysate (lanes 4 and 8):1-4. Anti-Human ASCT2/SLC1A5 (extracellular) Antibody (#ANT-083), (1:200)
5-8. Anti-Human ASCT2/SLC1A5 (extracellular) Antibody, preincubated with Human ASCT2/SLC1A5 (extracellular) Blocking Peptide (#BLP-NT083) (#BLP-NT083).
- Human HL-60 promyelocytic leukemia cells (2.5 µg).
ASCT2 is an alanine-serine-cysteine amino acid transporter and solute linked carrier family 1 member A5 (SLC1A5). It functions as an essential high-affinity glutamine transporter. It also functions as a Na+-dependent transporter for alanine, serine and cysteine. The transport process is electroneutral which involves the Na+-coupled influx of glutamine to the Na+-coupled efflux of another substrate such as alanine, serine or cysteine. ASCT2 is expressed various peripheral tissues such as the lung and kidney1,2. ASCT2 has an important contribution to the homeostasis of amino acid metabolism within tumor cells3.
ASCT2 seems to be up regulated in several cancerous tissues such as stomach, liver, kidney, breast, prostate, skin, colorectal, pancreatic, tongue and lung cancers. Studies have shown that ASCT2 is necessary for activating critical survival and cellular growth signaling cascades in cancer, which includes mTOR and ERK pathways. It has been shown that knockdown of ASCT2 in prostate cancer cell line xenograft models significantly inhibit tumor growth and metastasis in vivo. Thus, ASCT2 is a potential cancer therapeutic target1,2.